Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that, since January 1, 2020 , it has received proceeds of approximately $5.9 million as a result of the exercise of approximately 26.2 million previously issued Class B common share purchase warrants (the “Class B Warrants”).
March 5, 2020
· 3 min read